The AlphaLISA™ SureFire® Ultra™ Human Total EGF Receptor E746A-750 Deletion assay is a sandwich immunoassay for quantitative detection of total EGF Receptor E746A-750 Deletion in cellular lysates using Alpha Technology.
| Feature | Specification |
|---|---|
| Application | Cell Signaling |
| Protocol Time | 2h at RT |
| Sample Volume | 30 µL |
The AlphaLISA™ SureFire® Ultra™ Human Total EGF Receptor E746A-750 Deletion assay is a sandwich immunoassay for quantitative detection of total EGF Receptor E746A-750 Deletion in cellular lysates using Alpha Technology.
Loading...
The Epidermal Growth Factor Receptor (EGFR) is a receptor tyrosine kinase that binds EGF and related ligands to regulate cell proliferation, survival, differentiation, and migration. Upon ligand binding, EGFR undergoes dimerization and autophosphorylation, leading to activation of downstream signaling pathways including RAS/MAPK, PI3K/AKT, and PLCγ. EGFR plays a critical role in normal epithelial development and tissue homeostasis.
The E746_A750 deletion, one of the most prevalent EGFR exon 19 activating mutations, removes key amino acids within the kinase domain, destabilizing the inactive conformation of the receptor. This structural alteration results in ligand‑independent, constitutive EGFR activation and persistent downstream signaling that drives oncogenic transformation.
EGFR exon 19 deletions are particularly common in non‑small cell lung cancer (NSCLC) and are strongly associated with tumor growth, survival, and disease progression. These mutations represent well‑validated predictive biomarkers for response to EGFR‑targeted therapies. Small‑molecule tyrosine kinase inhibitors such as erlotinib, gefitinib, and osimertinib selectively inhibit mutant EGFR signaling and have become standard‑of‑care treatments for patients with EGFR exon 19‑deleted tumors, while monoclonal antibodies such as cetuximab and panitumumab are used in EGFR‑overexpressing cancers.
The AlphaLISA SureFire Ultra Human Total EGF Receptor E746A-750 Deletion Detection Kit is a sandwich immunoassay for the quantitative detection of total EGF receptor E746A-750 deletion in cellular lysates, using Alpha Technology.
Formats:
AlphaLISA SureFire Ultra kits are compatible with:
AlphaLISA SureFire Ultra kits can be used for:
The Total-AlphaLISA SureFire Ultra assay measures the expression level of a target protein in a biological sample (e.g. cell lysate).
The Total-AlphaLISA SureFire Ultra assay uses two antibodies which recognize two different distal epitopes on the target protein. AlphaLISA assays require two bead types: Acceptor and Donor Beads. Acceptor Beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure tag. Donor Beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of target protein, the two antibodies bring the Donor and Acceptor Beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor Bead, allowing for the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of protein present in the sample.
The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Total-AlphaLISA SureFire Ultra detection reagents. This protocol enables cell viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.
Detection of Total target protein with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining robust AlphaLISA SureFire Ultra quality.
The presence of the EGF Receptor E746-A750 deletion mutation was evaluated in various EGFR expressing cell lines using the AlphaLISA SureFire Ultra assay kit. Cells were grown to confluency in a T175 flask and lysed with Lysis Buffer at a density of 150,000 cells/mL. For the detection step, 10 µL of lysate (approximately 15,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at room temperature. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, EGF Receptor E746-A750 deletion mutation was only present in HCC-827 cells.
Cell lysate was prepared from HCC827 seeded in T175 flasks and cultured to confluence. Cells were lysed in 8 mL of Lysis Buffer for 10 minutes at RT with shaking.
Lysates were serially diluted in Lysis Buffer and assayed for EGF Receptor E746-A750 deletion levels using the AlphaLISA SureFire Ultra kit. For the detection step, 10 µL of lysate was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at room temperature. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
Approximate number of cells/datapoint is indicated. The dotted line represents assay background. The assay can detect Total EGF Receptor E746-A750 deletion expression down to 150 cells.
| Application |
Cell Signaling
|
|---|---|
| Automation Compatible |
Yes
|
| Brand |
AlphaLISA SureFire Ultra
|
| Detection Modality |
Alpha
|
| Product Group |
Kit
|
| Protocol Time |
2h at RT
|
| Sample Volume |
30 µL
|
| Shipping Conditions |
Shipped in Blue Ice
|
| Target |
EGF Receptor
|
| Target Class |
Phosphoproteins
|
| Target Species |
Human
|
| Technology |
Alpha
|
| Therapeutic Area |
Oncology
|
| Unit Size |
100 Assay Points
|
Are you looking for resources, click on the resource type to explore further.
The definitive guide for setting up a successful AlphaLISA SureFire Ultra assay
Several biological processes are regulated by...
Loading...
We are here to answer your questions.